Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
US8541169B2 · kind B2 · utility
3Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2007 |
| Grant date | Sep 24, 2013 |
| Priority date | — |
| Expiry date | Mar 9, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure describes alterations in ERG gene expression. ERG isoforms and promoter sequence of the ERG gene that are involved in, or associated with, prostate cancer are provided. The disclosure further provides therapeutic compositions and methods of detecting, diagnosing, prognosing, and treating prostate cancer, including biomarkers for detecting the expression of two or more of the following genes: PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.